Filing Details

Accession Number:
0001209191-17-066693
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-20 19:55:08
Reporting Period:
2017-12-18
Accepted Time:
2017-12-20 19:55:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649989 Oncobiologics Inc. ONS Biological Products, (No Disgnostic Substances) (2836) 383982704
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1664386 Pankaj Mohan C/O Oncobiologics, Inc.
7 Clarke Drive
Cranbury NJ 08512
President & Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-12-18 20,523 $1.17 7,254,838 No 4 S Direct
Common Stock Disposition 2017-12-19 83,608 $1.14 7,171,230 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 492,753 Indirect By spouse
Common Stock 39,405 Indirect By minor child
Common Stock 86,956 Indirect By Trust
Footnotes
  1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
  3. Includes 202,898 shares of the Issuer's common stock subject to RSUs that will vest on 12/31/2017, subject to continued service through such date.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 - $1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.